[68Ga]Ga-DOTA-FAPI-04作为新型广谱肿瘤及非肿瘤显像剂与[18F]FDG的对比研究
这项前瞻性研究纳入123例患者,同期行[68Ga]Ga-DOTA-FAPI-04与[18F]FDG PET/CT,比较对肿瘤及非肿瘤病灶的检出效能。结果显示,除骨髓瘤和淋巴瘤外,[68Ga]Ga-DOTA-FAPI-04对实体瘤原发、淋巴结及远处转移灶的摄取和检出率均显著优于[18F]FDG,对非肿瘤病灶两者检出效用相当。
要点
- FAPI对实体瘤原发、淋巴结和远处转移的SUVmax、灵敏度和准确率均高于FDG。
- FAPI对骨髓瘤和淋巴瘤的摄取和检出率低于FDG。
- FAPI与FDG对非肿瘤病灶和良性肿瘤的检出效用相当。
核心结论
- 除骨髓瘤和淋巴瘤外,[68Ga]Ga-DOTA-FAPI-04 PET/CT对实体瘤原发及转移灶的检出效能优于[18F]FDG PET/CT。
- 两种示踪剂对非肿瘤病灶的检出效用相当。
- [68Ga]Ga-DOTA-FAPI-04可作为广谱肿瘤及炎症显像剂用于临床。
研究设计与样本
- 前瞻性研究纳入123例患者(男69例、女54例,平均年龄56.11±11.94岁),同期行[68Ga]Ga-DOTA-FAPI-04与[18F]FDG PET/CT。
- 102例实体瘤患者中,82例为新诊断、20例为既往治疗;另8例血液系统肿瘤,13例未检出恶性肿瘤。
主要发现
- 实体瘤原发灶:FAPI较FDG的SUVmax为10.98±5.83 vs. 8.36±6.43(p<0.001),灵敏度97.67% vs. 84.89%,准确率96.59% vs. 82.95%(p=0.021)。
- 淋巴结转移:FAPI较FDG的SUVmax为10.50±5.98 vs. 8.20±6.29(p=0.011),灵敏度97.59% vs. 84.72%,准确率97.34% vs. 84.31%(p<0.001)。
- 远处转移:FAPI较FDG的SUVmax为9.64±6.45 vs. 6.74±4.83(p<0.001),灵敏度98.01% vs. 65.59%,准确率97.04% vs. 65.51%(p<0.001)。
- 骨髓瘤和淋巴瘤:FAPI较FDG的SUVmax为6.84±4.67 vs. 13.09±7.29(p<0.001),灵敏度50.65% vs. 96.75%,准确率51.28% vs. 95.51%(p<0.001)。
- 非肿瘤病灶和良性肿瘤:FAPI与FDG的SUVmax为6.40±3.95 vs. 5.74±15.78(p=0.729),灵敏度86.52% vs. 72.34%,准确率84.83% vs. 72.41%(p=0.007)。
关键数值与推荐
- 实体瘤原发灶灵敏度FAPI 97.67% vs. FDG 84.89%,准确率96.59% vs. 82.95%(p=0.021)。
- 淋巴结转移灵敏度FAPI 97.59% vs. FDG 84.72%,准确率97.34% vs. 84.31%(p<0.001)。
- 远处转移灵敏度FAPI 98.01% vs. FDG 65.59%,准确率97.04% vs. 65.51%(p<0.001)。
- 骨髓瘤和淋巴瘤灵敏度FAPI 50.65% vs. FDG 96.75%,准确率51.28% vs. 95.51%(p<0.001)。
- 非肿瘤病灶灵敏度FAPI 86.52% vs. FDG 72.34%,准确率84.83% vs. 72.41%(p=0.007)。
临床怎么用
- 对实体瘤原发及转移灶的评估可优先考虑[68Ga]Ga-DOTA-FAPI-04 PET/CT。
- 骨髓瘤和淋巴瘤的评估仍应选用[18F]FDG PET/CT。
- 非肿瘤病灶和良性肿瘤的检出两者效用相当,可结合临床选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to compare the detection performance of [68 Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT in the patients with various oncological and non-oncological lesions. METHODS: A total of 123 patients underwent contemporaneous [68 Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT were included in this prospective study. The maximum standard uptake value (SUVmax) was measured to compare oncological and non-oncological lesion uptake. The sensitivity, specificity, predictive values, and accuracy of [18F]FDG and [68 Ga]Ga-DOTA-FAPI-04 PET/CT for detecting primary, metastatic, and non-oncological lesions were calculated and compared to evaluate the detection efficacy. RESULTS: The study subjects consisted of 123 patients (69 men and 54 women; mean age 56.11 ± 11.94 years). Among the 102 patients with either newly diagnosed (82 patients) or previously treated solid tumor (20 patients), a total of 88 solid primary malignant tumors in 84/102 patients were detected. Two patients had two primary tumors each and 1 patient had three primary tumors. Among them, 58/102 and 43/102 patients had nodal (376 lesions) and distant metastases (406 lesions), respectively. Eight patients had hematological neoplasm. No malignant oncological diseases were detected in the remaining 13 patients. A total of 145 non-oncological lesions and benign tumors in 52/123 patients were detected incidentally. [68 Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated a significantly higher uptake and detection rate for the primary (SUVmax 10.98 ± 5.83 vs. 8.36 ± 6.43, p < 0.001; sensitivity 97.67 vs. 84.89%; and accuracy 96.59 vs. 82.95%, X2 = 0.538, p = 0.021), nodal (SUVmax 10.50 ± 5.98 vs. 8.20 ± 6.29, p = 0.011; sensitivity 97.59 vs. 84.72%; and accuracy 97.34 vs. 84.31%, X2 = 2.067, p < 0.001), and distant metastatic lesions (SUVmax 9.64 ± 6.45 vs. 6.74 ± 4.83; p < 0.001; sensitivity 98.01 vs. 65.59%; and accuracy 97.04 vs. 65.51%, X2 = 4.897, p < 0.001) of solid tumor than did [18F]FDG PET/CT. [68 Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated a lower activity (SUVmax: 6.84 ± 4.67 vs. 13.09 ± 7.29, p < 0.001) and detection rate (sensitivity 50.65 vs. 96.75%, and accuracy 51.28 vs. 95.51%, X2 = 5.166, p < 0.001) for multiple myeloma and lymphoma compared to [18F]FDG PET/CT. [68 Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET/CT PET/CT demonstrated a comparative activity (SUVmax 6.40 ± 3.95 vs. 5.74 ± 15.78, p = 0.729) and detection efficacy (sensitivity 86.52 vs. 72.34%, and accuracy 84.83 vs. 72.41%, X2 = 9.460, p = 0.007) for non-oncological lesion and benign tumor detection. CONCLUSIONS: Except for myeloma and lymphoma, [68 Ga]Ga-DOTA-FAPI-04 PET/CT showed a superior detection efficacy for detecting various primary and metastatic lesions than [18F]FDG PET/CT. A comparative detection utility for non-oncological lesion was obtained with both tracers. [68 Ga]Ga-DOTA-FAPI-04 could be used as a broad-spectrum tumor and inflammatory imaging agent in the clinical especially for various solid tumors and non-oncological lesions.
引用
- Lan L, Liu H, Wang Y, et al. The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG. Eur J Nucl Med Mol Imaging. 2021. PMID: 34410435. doi:10.1007/s00259-021-05522-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。